C4U is pleased to announce that the patent for the invention “METHOD FOR PRODUCING KNOCK-IN CELL“ related to CRISPR-Cas3 genome editing technology, for which C4U has been granted exclusive licenses with sublicensing rights from the University of Osaka, was issued in China on July 11, 2025 as Patent No. ZL 2020 8 0025993.1.
This invention is one of the foundational intellectual property elements of CRISPR-Cas3 technology, along with the inventions “METHOD FOR MANUFACTURING DNA-EDITED EUKARYOTIC CELL, AND KIT USED IN METHOD” and "GENOME EDITING METHOD", that have already been patented in Japan and other countries.
This invention has also been patented in Japan (Patent No. 7426120), now this registration in China marks the first registration outside of Japan.
C4U will continue to strengthen its intellectual property foundation surrounding CRISPR-Cas3 technology worldwide and accelerate its application in a wide range of fields, including pharmaceutical field.
About C4U Corporation
C4U is a privately held biotech company based in Osaka, Japan, and is focused on the development of safe and efficient gene therapies utilizing its proprietary next generation CRISPR-Cas3 gene editing platform. In comparison to the CRISPR-Cas9 platform, CRISPR-Cas3 presents the distinct benefits of: 1) no off-target by the higher selectivity of deletion site (improved safety); 2) efficient knockouts by the larger deletion of gene sequences; and 3) an entirely independent patent portfolio. C4U has been granted a worldwide exclusive license to CRISPR-Cas3 by the University of Osaka for use in eukaryotic cells thus simplifying sublicensing transactions which is in sharp contrast to the complex and heavily litigated CRISPR-Cas9 patent landscape.
